Local recommendations (Gastro-intestinal)
For DMARD Shared Care click here
Chronic bowel disorders
| Recommendation | Approval date | Review date |
| St Marks formula electrolyte solution (updated) | February 2018 | February 2022 |
| PR2019-07 EKPG Recommendation Probiotics for adults with lactose intolerance IBS and IBD | April 2019 | April 2022 |
| Kent and Medway INFLAMMATORY BOWEL DISEASE (IBD) (ADULTS) HIGH-COST DRUG (HCD) PATHWAY | August 2023 | August 2025 |
Constipation
| Recommendation | Approval date | Review date |
| Naloxegol -EKPG Recommendation | Oct 2015 | April 2021 |
| Lubiprostone Prescribing Guidelines - EKPG | Sept 2014 | April 2021 |
| Place of Linaclotide in NICE IBS pathway | October 2020 | October 2021 |
| 020.20 PR 2019-16 Linaclotide for irritable bowl syndrome with constipation (IBS-C) in adults | July 2019 | July 2020 |
Diarrhoea
| Recommendation | Approval date | Review date |
| EKPG Recommendation - Diarrhoea Assessment and Management in Adults | April 2016 | April 2019 |
Disorders of gastric acid and ulceration
| Recommendation | Approval date | Review date |
| Hypomagnesaemia in Adults – Primary Care Guide | August 2023 | August 2025 |
GI Smooth Muscle Spasm
| Recommendation | Approval date | Review date |
| Gastro-intestinal (GI) Anti-spasmodics – Dicycloverine and Propantheline prescribing not supported | October 2023 | October 2025 |
Liver disorders and related conditions
| Recommendation | Approval date | Review date |
| Rifaximin GP summary, EKPG recommendation | January 2016 | April 2021 |
| Rifixamin pathway v1.3 EKPG recommendation | April 2019 | April 2022 |
Rectal and anal disorders
| Recommendation | Approval date | Review date |
| EKPG Pathway for the management of Anal Fissures in primary care | June 2017 | June 2020 |
| EKPG Recommendation, Botulinum Toxin for chronic anal fissures | May 2016 | April 2021 |
Ventral hernias
| Recommendation | Approval date | Review date |
| PRGC PR 2022-15 BTX for ventral hernia | June 2022 | June 2024 |